Search

Your search keyword '"Bregni M."' showing total 646 results
Start Over Author "Bregni M."
646 results on '"Bregni M."'

101. Reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas: Impact of pre-transplantation factors on long-term outcome

Author

Corradini P, Dodero A, Bregni M, Olivieri A, Farina L, Valagussa P, Scime R, Locasciulli A, Patriarca F, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Bregni, M, Ciceri, Fabio, Olivieri, A, Farina, L, Valagussa, P, Scime, R, Locasciulli, A, Patriarca, F, Gianni, Am, and Tarella, C.

Published
2005

102. Receptor repertoire reconstitution suggests acquisition of patient-specific tolerance by natural killer cells arising from hematopoietic progenitor stem cells after haploidentical transplantation

Author

Vago L, Terlizzi SD, Zino E, Magnani CF, Stanghellini MTL, Magnani Z, Mazzi B, Clerici D, BONDANZA , ATTILIO, Bregni M, Rossini S, Peccatori J, BONINI , MARIA CHIARA, CICERI , FABIO, BORDIGNON, CLAUDIO, Fleischhauer K., Vago, L, Terlizzi, Sd, Zino, E, Magnani, Cf, Stanghellini, Mtl, Magnani, Z, Mazzi, B, Clerici, D, Bondanza, Attilio, Bregni, M, Rossini, S, Peccatori, J, Bonini, MARIA CHIARA, Ciceri, Fabio, Bordignon, Claudio, and Fleischhauer, K.

Published
2005

103. Early immune reconstitution and abrogation of GvHD after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hemopoietic stem cell transplantation

Author

CICERI , FABIO, BONINI , MARIA CHIARA, BONDANZA , ATTILIO, Magnani Z, Bernardi M, Peccatori J, Crippa F, Stampino CG, Bregni M, BORDIGNON, CLAUDIO, Raffaele HS, Ciceri, Fabio, Bonini, MARIA CHIARA, Bondanza, Attilio, Magnani, Z, Bernardi, M, Peccatori, J, Crippa, F, Stampino, Cg, Bregni, M, Bordignon, Claudio, and Raffaele, Hs

Published
2004

105. Brief report: Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma

Author

Clementi R, Dianzani U, Dupre L, Dianzani I, Cometa A, Chiocchetti A, Sabbadini MG, Rugarli C, Maccario R, Locatelli F, Danesino C, Ferrarini M, Bregni M., DAGNA , LORENZO, PONZONI , MAURILIO, CICERI , FABIO, Clementi, R, Dagna, Lorenzo, Dianzani, U, Dupre, L, Dianzani, I, Ponzoni, Maurilio, Cometa, A, Chiocchetti, A, Sabbadini, Mg, Rugarli, C, Ciceri, Fabio, Maccario, R, Locatelli, F, Danesino, C, Ferrarini, M, and Bregni, M.

Abstract

27-year-old man with the autoimmune lymphoproliferative syndrome and a large-B-cell lymphoma had heterozygous mutations in the Fas and perforin (Prf1) genes. The Fas mutation was inherited from his healthy father and was also carried by his healthy brother, whereas the Prf1 mutation was inherited from his healthy mother. The combined effect of the two mutant genes may have contributed to the development of the autoimmune lymphoproliferative syndrome and lymphoma in this patient. A 27-year-old man with the autoimmune lymphoproliferative syndrome and a large-B-cell lymphoma had heterozygous mutations in the Fas and perforin (Prf1) genes. The Fas mutation was inherited from his healthy father and was also carried by his healthy brother, whereas the Prf1 mutation was inherited from his healthy mother. The combined effect of the two mutant genes may have contributed to the development of the autoimmune lymphoproliferative syndrome and lymphoma in this patient.

Published
2004

109. Effect of age and previous autologous transplant on treatment-related mortality and GVHD in 140 patients treated with reduce-intensity conditioning and allograft for advanced hematological malignancies

Author

Corradini P, Zallio F, Mariotti J, Valagussa P, Dodero A, Bregni M, Bacigalupo A, Lucesole M, Patriarca F, Rambaldi A, Scime R, Bandini G, Gianni AM, Tarella C, Olivieri A., CICERI , FABIO, Corradini, P, Zallio, F, Mariotti, J, Valagussa, P, Dodero, A, Bregni, M, Ciceri, Fabio, Bacigalupo, A, Lucesole, M, Patriarca, F, Rambaldi, A, Scime, R, Bandini, G, Gianni, Am, Tarella, C, and Olivieri, A.

Published
2004

110. Infusion of HSV-Tk engineered donor lymphocytes provide early immune reconstitution and abrogation of GvHD after haploidentical hemopoietic stem cell transplantation

Author

CICERI , FABIO, BONINI , MARIA CHIARA, BONDANZA , ATTILIO, Magnani Z, Bernardi M, Peccatori J, Crippa F, Stampino CG, Bregni M, BORDIGNON, CLAUDIO, Raffaele HS, Ciceri, Fabio, Bonini, MARIA CHIARA, Bondanza, Attilio, Magnani, Z, Bernardi, M, Peccatori, J, Crippa, F, Stampino, Cg, Bregni, M, Bordignon, Claudio, and Raffaele, Hs

Published
2004

111. Reduced-intensity conditioning followed by allografting in patients with advanced haematological malignancies older than 60 years

Author

Olivieri A, Lucesole M, Cecchi S, Dodero A, Bregni M, Tarella C, Falda M, Locasciulli A, Scime R, Patriarca F, Casini M, Bacigalupo A, Corradini P., CICERI , FABIO, Olivieri, A, Lucesole, M, Cecchi, S, Dodero, A, Ciceri, Fabio, Bregni, M, Tarella, C, Falda, M, Locasciulli, A, Scime, R, Patriarca, F, Casini, M, Bacigalupo, A, and Corradini, P.

Published
2004

114. Mobilized blood CD341 cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice

Author

DEOLA S, SCARAMUZZA S, BIROLO RS, CARBALLIDO PERRIG N, FICARA F, MOCCHETTI C, DANDO, J, CARBALLIDO JM, BORDIGNON , CLAUDIO, RONCAROLO , MARIA GRAZIA, BREGNI M, AIUTI , ALESSANDRO, Deola, S, Scaramuzza, S, Birolo, R, CARBALLIDO PERRIG, N, Ficara, F, Mocchetti, C, Dando, J, Carballido, Jm, Bordignon, Claudio, Roncarolo, MARIA GRAZIA, Bregni, M, and Aiuti, Alessandro

Abstract

We developed a clinically applicable gene transfer procedure into mobilized peripheral blood (MPB) CD34(+) hematopoietic progenitor cells, based on single viral exposure and selection of engineered cells. CD34(+) cells were transduced with a retroviral vector carrying the truncated form of the nerve growth factor receptor (DNGFR) marker gene, and immunoselected for DNGFR expression. Optimal time and procedure for viral exposure, length of culture, and transgene expression of MPB CD34(+) cells were determined using in vitro assays. The multipotent capacity of MPB CD34(+)-transduced cells was demonstrated in the SCID-hu bone/liver/thymus mouse model. Transduced DeltaNGFR(+) cells retained 50% of long-term culture-colony forming cells (LTC-CFC) compared to unmanipulated CD34(+) cells. In SCID-hu mice, 52% of CD45(+) cells, 27% of CD34(+) cells, 49% of B cells, and more than 50% of T cells were derived from transplanted CD34(+)/DeltaNGFR(+) cells. Furthermore, transplantation of purified transduced cells greatly reduced the competition with untransduced progenitors occurring in unselected grafts. These data demonstrate that MPB CD34(+) cells, transduced with a single viral exposure and selected by transgene expression, retain multilineage reconstitution capacity and remarkable transgene expression.

Published
2004

115. Graft-versus-tumour effect following reduced-intensity allogeneic stem cell transplantation in renal cell cancer

Author

Ringden, O., Niederwieser, D., Demirer, T., Rosti, G., Corradini, P., Lenhoff, S., Brunes, M., Sierra, J., Martino, R., Siena, J., Ciceri, F., Carminati, O., Remberger, M., Paolo Pedrazzoli, Peccatori, J., Bregni, M., Barkholt, L., Barkholt, L, Bregni, M, Peccatori, J, Pedrazzoli, P, Remberger, M, Carminati, O, Ciceri, Fabio, Siena, J, Martino, R, Sierra, J, Brunes, M, Lenhoff, S, Corradini, P, Rosti, G, Demirer, T, Niederwieser, D, and Ringden, O.

Published
2004

116. Molecular follow-up of patients treated with HSV-TK/Delta LNGFR engineered donor lymphocytes after allogeneic stem cell transplantation

Author

BONINI , MARIA CHIARA, CICERI , FABIO, Magnani Z, Recchia A, Urbinati F, Muraro S, Sartori S, Bernardi M, Pescarollo A, Gallo Stampino C, Bregni M, BORDIGNON, CLAUDIO, Mavilio F., Bonini, MARIA CHIARA, Magnani, Z, Recchia, A, Urbinati, F, Muraro, S, Sartori, S, Ciceri, Fabio, Bernardi, M, Pescarollo, A, Gallo Stampino, C, Bregni, M, Bordignon, Claudio, and Mavilio, F.

Published
2004

118. Graft-versus-tumor effect following reduced-intensity allogeneic stem cell transplantation in renal cell cancer. On behalf of the EBMT solid tumours working party

Author

Niederwieser, D., Ringden, O., Demirer, T., Rosti, G., Corradini, P., Bekassy, An, Brune, M., Sierra, J., Martino, R., Siena, S., Ciceri, F., Carminati, O., Remberger, M., Paolo Pedrazzoli, Peccatori, J., Barkholt, L., Bregni, M., Bregni, M, Barkholt, L, Peccatori, J, Pedrazzoli, P, Remberger, M, Carminati, O, Ciceri, Fabio, Siena, S, Martino, R, Sierra, J, Brune, M, Bekassy, An, Corradini, P, Rosti, G, Demirer, T, Ringden, O, and Niederwieser, D.

Published
2003

119. Non-TBI conditioning for family haploidentical allogeneic stem cell transplantation: A single centre experience in 20 patients

Author

CICERI , FABIO, Zappone E, BONINI , MARIA CHIARA, Peccatori J, Bernardi M, Pescarollo A, Stanghellini MTL, Corti C, Lunghi F, Fleischhauer K, Callegaro L, Servida P, Bregni M, BORDIGNON, CLAUDIO, Ciceri, Fabio, Zappone, E, Bonini, MARIA CHIARA, Peccatori, J, Bernardi, M, Pescarollo, A, Stanghellini, Mtl, Corti, C, Lunghi, F, Fleischhauer, K, Callegaro, L, Servida, P, Bregni, M, and Bordignon, Claudio

Published
2003

120. Hsv-Tk engineered donor lymphocytes provide early immune reconstitution and control of Gvhd after haplo-identical hemopoietic stem cell transplantation

Author

BONINI , MARIA CHIARA, CICERI , FABIO, Apperley J, Slavin S, Marktel S, BONDANZA , ATTILIO, Magnani Z, Perna SK, Zappone E, Pescarollo A, Callegaro L, Bernardi M, Gallo Stampino C, Salomoni M, Turchetto L, Servida P, Bregni M, BORDIGNON, CLAUDIO, Bonini, MARIA CHIARA, Ciceri, Fabio, Apperley, J, Slavin, S, Marktel, S, Bondanza, Attilio, Magnani, Z, Perna, Sk, Zappone, E, Pescarollo, A, Callegaro, L, Bernardi, M, Gallo Stampino, C, Salomoni, M, Turchetto, L, Servida, P, Bregni, M, and Bordignon, Claudio

Published
2003

123. HSV-TK engineered donor lymphocytes provide early immune reconstitution after haplo-identical hemopoietic stem cell transplantation

Author

CICERI , FABIO, BONINI , MARIA CHIARA, Marktel S, Magnani Z, BONDANZA , ATTILIO, Zappone E, Servida P, Pescarollo A, Callegaro L, Stampino CG, Bernardi M, Bregni M, BORDIGNON, CLAUDIO, Ciceri, Fabio, Bonini, MARIA CHIARA, Marktel, S, Magnani, Z, Bondanza, Attilio, Zappone, E, Servida, P, Pescarollo, A, Callegaro, L, Stampino, Cg, Bernardi, M, Bregni, M, and Bordignon, Claudio

Published
2003

125. Reduced-intensity conditioning with low dose ATG or alemtuzumab followed by allogeneic PBSC: A salvage therapy with an encouraging response rate and limited toxicity in relapsed/refractory multiple myeloma

Author

Corradini P, Milani R, Montefusco V, Peccatori J, Mariotti J, Olivieri A, Soligo D, Gianni AM, Perfetti V, Bregni M., CICERI , FABIO, Corradini, P, Milani, R, Ciceri, Fabio, Montefusco, V, Peccatori, J, Mariotti, J, Olivieri, A, Soligo, D, Gianni, Am, Perfetti, V, and Bregni, M.

Published
2002

129. Abrogation of GvHD and early immune reconstitution after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hemopoietic stem cell transplantation

Author

BONINI , MARIA CHIARA, CICERI , FABIO, BORDIGNON, CLAUDIO, Marktel S, Magnani Z, Cazzaniga S, Zappone E, Servida P, Pescarollo A, Callegaro L, Bernardi M, Bregni M, Bonini, MARIA CHIARA, Ciceri, Fabio, Marktel, S, Magnani, Z, Cazzaniga, S, Zappone, E, Servida, P, Pescarollo, A, Callegaro, L, Bernardi, M, Bregni, M, and Bordignon, Claudio

Published
2002

130. Reduced-intensity conditioning followed by allogeneic transplantation is an effective salvage treatment for patients with hematologic malignancies failing a previous autograft

Author

Corradini P, Tarella C, Olivieri A, Dodero A, Voena C, Leoni P, Zallio F, Devizzi L, Rambaldi A, Sajeva M, Gianni A, Bregni M., CICERI , FABIO, BORDIGNON, CLAUDIO, Corradini, P, Tarella, C, Olivieri, A, Dodero, A, Voena, C, Leoni, P, Zallio, F, Ciceri, Fabio, Devizzi, L, Rambaldi, A, Sajeva, M, Bordignon, Claudio, Gianni, A, and Bregni, M.

Published
2002

131. Reinfusion of Hsv-TK engineered donor lymphocytes after haplo-identical hemopoietic stem cell transplantation provide early immune reconstitution without GvHD

Author

CICERI , FABIO, BONINI , MARIA CHIARA, Marktel S, Traversari C, Magnani Z, Zappone E, Servida P, Pescarollo A, Corradini P, Peccatori J, Bernardi M, Bregni M, BORDIGNON, CLAUDIO, Ciceri, Fabio, Bonini, MARIA CHIARA, Marktel, S, Traversari, C, Magnani, Z, Zappone, E, Servida, P, Pescarollo, A, Corradini, P, Peccatori, J, Bernardi, M, Bregni, M, and Bordignon, Claudio

Published
2001

134. Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in leukemias and lymphomas

Author

Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Moira L, Dodero A, Rambaldi A, Sajeva MR, Tresoldi MIO, Bregni M., CICERI , FABIO, BORDIGNON, CLAUDIO, Corradini, P, Tarella, C, Olivieri, A, Gianni, Am, Voena, C, Zallio, F, Ladetto, M, Falda, M, Moira, L, Dodero, A, Ciceri, Fabio, Rambaldi, A, Sajeva, Mr, Tresoldi, Mio, Bordignon, Claudio, and Bregni, M.

Published
2001

135. CMV reactivation in patients undergoing reduced-intensity allogeneic stem cell transplantation: Association with graft-versus-host disease and transplant related mortality

Author

Peccatori J, Assanelli A, Dodero A, Lillo F, Pescarollo A, Servida P, Corti C, Camba L, BORDIGNON, CLAUDIO, Corradini P, Bregni M., CICERI , FABIO, Peccatori, J, Assanelli, A, Dodero, A, Lillo, F, Pescarollo, A, Servida, P, Corti, C, Camba, L, Ciceri, Fabio, Bordignon, Claudio, Corradini, P, and Bregni, M.

Published
2001

136. The EBMT activity survey: 1990-2010

Author

Passweg, Jr, Baldomero, H, Gratwohl, A, Bregni, M, Cesaro, Simone, Dreger, P, Witte, Td, Farge Bancel, D, Gaspar, B, Marsh, J, Mohty, M, Peters, C, Tichelli, A, Velardi, A, de Elvira CR, Falkenburg, F, Sureda, A, Madrigal, A, for the European Group for Blood, and Marrow, Transplantation

Subjects
survey activity, transplant, stem cell transplantation, survey activity, transplant, europe, europe, stem cell transplantation
Published
2012

137. TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) WITH HIGH DOSE IMMUNOSUPPRESSIVE TREATMENT USING CYCLOPHOSPHAMIDE WITH AUTOLOGOUS HAEMOPOIETIC STEM CELL RESCUE

Author

Ciceri, F., Magnani, G., Zappone, E., Servida, P., Corradini, P., Bregni, M., Comi, G., Roncarolo, M.G., and Bordignon, C.

Subjects
Demyelinating diseases -- Care and treatment, Hematopoietic stem cells -- Transplantation, Health, Care and treatment
Abstract

Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is considered to be an autoimmune disorder. Current treatment regimens leave 4-30% of patients with CIDP with moderate or severe disability. Conventional dose immunosuppressive [...]

Published
2001

138. Infusione intra-arteriosa epatica in ipossia di mitomicina-C per il trattamento di metastasi epatiche multiple e di tumori primitivi inoperabili: Esperienza mono-centrica in 42 pazienti

Author

Baggiani, A., Ierardi, A. M., Caspani, B., Motta, F., Toniolo, D., Belloni, P., Setola, E., Campagnoli, E., Tempini, S., Crocchiolo, R., Bregni, M., and Belli, Lorenzo

Subjects
Adult, Male, Infusions, Mitomycin, Disease-Free Survival, Hepatic Artery, Antibiotics, Nuclear Medicine and Imaging, Humans, Neoplasm Metastasis, Aged, Retrospective Studies, Inpatients, Intra-Arterial, Liver Neoplasms, Hypoxic liver perfusion, Mitomycin-C, Multifocal liver metastases, Antibiotics, Antineoplastic, Cell Hypoxia, Feasibility Studies, Female, Length of Stay, Middle Aged, Quality of Life, Radiography, Treatment Outcome, Infusions, Intra-Arterial, Radiology, Nuclear Medicine and Imaging, Antineoplastic, Radiology
Published
2011

140. Long-Term Safety and Efficacy of Gene Therapyfor Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency

Author

Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L, Scaramuzza, S, Andolfi, G, Mirolo, M, Brigida, I, Tabucchi, A, Carlucci, F, Eibl, M, Aker, M, Slavin, S, Al Mousa, H, Ghonaium, A, Ferster, A, A, Duppenthaler, A, Luigi, N, Wintergerst, U, H. Buckley, R, Bregni, M, Marktel, S, Valsecchi, M, Rossi, P, Ciceri, F, Miniero, R, Bordignon, C, and Roncarolo, M

Subjects
Settore MED/38 - Pediatria Generale e Specialistica
Published
2009

142. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients

Author

guido cavaletti, Bogliun, G., Zincone, A., Marzorati, L., Melzi, P., Frattola, L., Marzola, M., Bonazzi, C., Cantù, M. G., Chiari, S., Galli, A., Bregni, M., Gianni, M. A., Cavaletti, G, Bogliun, G, Zincone, A, Marzorati, L, Melzi, P, Frattola, L, Marzola, M, Bonazzi, C, Cantù, M, Chiari, S, Galli, A, Bregni, M, and Gianni, M

Subjects
Neurons, Ovarian Neoplasms, Adult, Prognosi, Ovarian Neoplasm, Antineoplastic Agents, Neuron, Middle Aged, Prognosis, Carboplatin, Antineoplastic Agent, Humans, Female, Human
Abstract

Background: Hematopoietic toxicity of high-dose carboplatin (HD-CBDCA) chemotherapy can be managed effectively with autologous blood cell support, but no conclusive data are available on its the neuro- and ototoxicity. Patients and methods: We determined the neuro- and ototoxicity of HD-CBDCA in 10 patients affected by advanced ovarian cancer. HD-CBDCA was delivered as 24-hour continous infusion or as 5-day schedules. Each patient underwent an extended clinical and instrumental neurological and otological evaluation before, during and after treatment. Results: After HD-CBDCA only I patient had a clinically-evident peripheral neuropathy, while 3 additional patients had only distal paresthesias. Neurophysiological examination evidenced mild, although diffuse, sensory nerve impairment. Motor nerve impairment war also occasionally observed All the sensory and motor pathological changes had a favorable course during the follow-up period. Ototoxicity was more severe than neurotoxicity and, in one case it was dose-limiting and audiologic impairment tended to remain constant also in the follow-up period. Conclusions: HD-CBDCA treatment can be tolerated by most of the patients, but careful monitoring of neuro- and, especially, ototoxicity should be planned

Published
1998

146. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin N.C., Labopin M., Rocha V., Arcese W., Beksac M., Gluckman E., Ringden O., Ruutu T., Reiffers J., Bandini G., Falda M., Zikos P., Willemze R., Frassoni F., Abecasis M., Abráhamová J., Afanassiev B.V., Aglietta M., Alabdulaaly A., Aleinikova O., Paolo Alessandrino E., Al Shemmari S.H., Amadori D., Amadori S., Amos T., Andolina M., Andreesen R., Angelucci E., Anhuf J., Arnold R., Arpaci F., Attal M., Azevedo W., Azim H.A., Baccarani M., Bacigalupo A., Barbui T., Bargetzi M., Barnard D.L., Bartsch H.H., Baruchel A., Battista C., Bay J.-O., Bayik M., Bazarbachi A., Beguin Y., López J.L.B., Benedek I., Benedetti F., Bengala C., Berrebi A., Besalduch J., Biesma D., Biron P., Björkholm M., Blaise D., Blesing N.E., Boasson M., Bobev D., Boccadoro M., Bolaman Z., Boogaerts M.A., Bordessoule D., Bosi A., Aida B.S., Bourhis J.H., Bourikas G., Bowen D.T., Bregni M., Bries G., Brinch L., Brittain D., Bron D., Brune M., Bullorsky E.O., Bunjes D., Burdach S., Burnett A.K., Buzyn A., Caballero D., Cagirgan S., Cahn J.-Y., Canepa C.O., Cao A., Carella A.M., Carrera F.D., Carret A.-S., Cascinu S., Castel V., Caswell M., Cavanna L., Cetto G.L., Chapuis B., Chasty R., Chen Y.-C., Chisesi T., Chopra R., Chybicka A., Clark R.E., Colombat P., Colovic M.D., Constenla-Figueiras M., Contreras M., Contu L., Cordonnier C., Cornelissen J.J., Cornish J., Coser P., Costa N., Coze C., Craddock C., Crown J., Culligan D.J., Danova M., Darbyshire P.J., Davies J.M., de Bock R., de Pablos Gallego J.M., De Prijck B., de Revel T., De Rossi G., De Souza C.A., Deb G., Degos L., Demuynck H., Dervenoulas I., Di Bartolomeo P., Di Renzo N., Diaz M.A., Diehl V., Diez-Martin J.L., Dincer S., Giorgio D., Dmoszynska A., Doelken G., Peter P.D., Dulley F., Easow J., Ebell W., Efremidis A., Ehninger G., Eichler H., Eimermacher H., Enno A., Errazquin L., Aguado J.E., Everaus H., Fagioli F., Fanin R., Fassas A., Fasth A., Faulkner L.B., Fauser A.A., Feldman L., Feremans W., Ferhanoglu B., Fernández M.N., Fernández-Ranada J.M., Ferrant A., Ferrara F., Finke J., Fischer A., Fischer J., Fitzsimons T., Floristan F., Forjaz de Lacerda J.M.F., Fossati-Bellani F., Fosser V., Franklin I., Freund M., Frickhofen N., Gabbas A., Gadner H., Gallamini A., Galvin M.C., López J.G., García-Conde J., Gaska T., Gastl G., Gedikoglu G., Ghavamzadeh A., Gianni A., Gibson B.E., Gil J.L., Gilleece M.H., Gisselbrecht C., Glass B., Gmür J., Göbel U., Goldman J.M., Goldstone A.H., San Miguel J.D.G., González-López M.-A., Grafakos S., Gramatzki M., Grañena A., Gratecos N., Gratwohl A., Greinix H.T., Gugliotta L., Guilhot F., Guimaraes J.E., Gülbas Z., Gulyuz O., Gurman G., Gutierrez M.M., Haas R., Hamladji R.-M., Hamon M.D., Hansen N.E., Harhalakis N., Harousseau J.L., Hartenstein R., Hartmann C.O., Hausmaninger H., Haznedar R., Heit W., Hellmann A., Herrmann R.P., Hertenstein B., Hess U., Hinterberger W., Ho A.D., Hoelzer D., Holowiecki J., Horst H.-A., Hossfeld D.K., Huebsch L., Hunter A.E., Iacopino P., Iannitto E., Indrák K., Iriondo A., Izzi T., Jackson G.L., Jacobs P., Jacobsen N., Janvier M., Jebavy L., Joensuu H., Joerg S., Jones F.G.C., Jouet J.P., Joyner M.V., Juliusson G., Jürgens H., Kalayoglu-Besisik S., Kalman N., Kalmanti M., Kansoy S., Kansu E., Kanz L., Karianakis G., Kernéis Y., Khalifeh O., Khomenko V., Kienast J., Killick S., Kirchner H.H., Klingebiel T., Knauf W., Koenigsmann M., Koistinen P., Koivunen E., Kolb H.-J., Kolbe K., Koller E., Komarnicki M., Koscielniak E., Kovacsovics T., Kowalczyk J.R., Koza V., Kozak T., Kugler J., Kuliczkowski K., Kvaloy S., Labar B., Laciura P., Palacios J.J.L., Lakota J., Lambertenghi D.G., Lange A., Lanza F., Isasti R.L., Lauria F., Le Moine F., Leblond V., Lelli G., Lenhoff S., Leon L.A., Leoncini-Franscini L., Leone G., Leoni P., Levis A., Leyvraz S., Liberati M., Link H., Linkesch W., Liso V., Lisukov I.A., Littlewood T., Ljungman P., Locatelli F., Losonczy H., Lotz J.-P., Ludwig H., Lukac J., Lutz D., Macchia P., Madrigal A., Maiolino A., Majolino I., Eloy-García J.M., Malesevic M., Mandelli F., Marc A., Marcus R., Marianska B., Markuljak I., Marsh J.C.W., Martelli M.F., Marti Tutusaus J.M., Martin S., Martin M., Martinelli G., Martínez-Rubio A.M., Martoni A., Maschan A., Maschmeyer G., Masszi T., Mazza P., McCann S., Meier C.R., Messina C., Mettivier V., Metzner B., Michallet M., Michieli M., Michon J., Milligan D.W., Milone J.H., Giuseppe G.M., Minigo H., Mistrik M., Moicean A.D., Monfardini S., Montserrat E., Moraleda Jimenez J.M., Morales-Lazaro A., Morandi S., Morra E., Mufti G.J., Musso M., Nagler A., Nalli G., Naparstek E., Narni F., Nenadov-Beck M., Neubauer A., Newland A.C., Niederwieser D., Niethammer D., Noens L.A., Nousiainen T., Novik A., Novitzky N., Occhini D., Odriozolas J., Ojanguren J.M., O’meara A., Onat H., Orchard K., Ortega J.J., Osieka R., Ossenkoppele G.J., Othman B., Ovali E., Ozcebe O.I., Ozerkan K., Ozturk A., Papatryfonos A., Parker J.E., Pastore M., Patrone F., Patton N., Pejin D., Peñarrubia M.J., Equiza E.P., Peschel C., Pession A., Pigaditou A., Pignon B., Pihkala U., Pimentel P., Pitini V., Podoltseva E., Pogliani E.M., Anna A.P., Porta F., Potter M., Powles R., Prentice G.H., Pretnar J., Ptushkin V., Quarta G., Reiter A., Remes K., Reykdal S., Santasusana J.M.R., Rifón J., Rio B., Rizzoli V., Robak T., Robinson A.J., Rodeghiero F., Rodríguez Fernández J.M., Rombos Y., Romeril K.R., Rosenmayr A., Rossi J.F., Rosti G., Rotoli B., Rowe J.M., Russell N.H., Ryzhak O., Rzepecki P., Saglio G., Salwender H., Samonigg H., Santoro A., Sanz M.A., Sayer H.G., Scanni A., Schaafsma M.R., Schaefer U.W., Schanz U., Schattenberg A., Schey S.A.M., Schlimok G., Schmoll H.-J., Schots R., Schouten H., Schwarer A.P., Schwerdtfeger R., Scimè R., Segel E., Seger R., Selleslag D., Serban M., Shamaa S., Shaw P.J., Siegert W., Siena S., Sierra J., Simonsson B., Singer C.R.J., Sirchia G., Skotnicki A.B., Slavin S., Snowden J., Sotto J.J., Tanyeli A., Tedeschi L., Tidefelt U., Tissot J.-D., Tobler A., Tomas J.F., Torres J.P., Torres G.A., Touraine J.-L., Trneny M., Uderzo C., Unal E., Unal A., Undar L., Urban C., Van den Berg H., van Marwijk K.M., Vellenga E., Venturini M., Verdonck L.F., Veys P., Vilardell J., Vinante O., Visani G., Vitek A., Vivancos P., Volpe E., Vora A., Vorlicek J., Vowels M., Vujic D., Wachowiak J., Wagner T., Wahlin A., Walewski J., Wandt H., Weissinger F., Wijermans P.W., Wiktor-Jedrzejczak W., Will A.M., Woell E., Wörmann B., Yaniv I., Yesilipek M.A., Yilmaz U., Yong A., Zachée P., Zambelli A., Zander A.R., Zintl F., Zoumbos N.C., Çukurova Üniversitesi, Maltepe Üniversitesi, and Ege Üniversitesi

Subjects
Myeloid, Male, Pathology, Time Factors, Graft vs Host Disease, Biochemistry, Gastroenterology, Blood cell, Bone Marrow, Child, Bone Marrow Transplantation, Leukemia, Remission Induction, Hematology, Middle Aged, Prognosis, Leukemia, Myeloid, Acute, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, medicine.anatomical_structure, Treatment Outcome, Child, Preschool, Female, Stem cell, InformationSystems_MISCELLANEOUS, Homologous, Adult, medicine.medical_specialty, Adolescent, Immunology, Acute, Disease-Free Survival, Internal medicine, medicine, Transplantation, Homologous, Humans, Preschool, Aged, Transplantation, business.industry, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Cell Biology, medicine.disease, Peripheral blood, Histocompatibility, Multivariate Analysis, Stem Cell Transplantation, ComputingMethodologies_PATTERNRECOGNITION, Myelocytic leukemia, Bone marrow, business, Settore MED/15 - Malattie del Sangue
Abstract

PubMed ID: 12829583, Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

147. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin, N.C. Labopin, M. Rocha, V. Arcese, W. Beksac, M. Gluckman, E. Ringden, O. Ruutu, T. Reiffers, J. Bandini, G. Falda, M. Zikos, P. Willemze, R. Frassoni, F. Abecasis, M. Abráhamová, J. Afanassiev, B.V. Aglietta, M. Alabdulaaly, A. Aleinikova, O. Paolo Alessandrino, E. Al Shemmari, S.H. Amadori, D. Amadori, S. Amos, T. Andolina, M. Andreesen, R. Angelucci, E. Anhuf, J. Arnold, R. Arpaci, F. Attal, M. Azevedo, W. Azim, H.A. Baccarani, M. Bacigalupo, A. Barbui, T. Bargetzi, M. Barnard, D.L. Bartsch, H.H. Baruchel, A. Battista, C. Bay, J.-O. Bayik, M. Bazarbachi, A. Beguin, Y. López, J.L.B. Benedek, I. Benedetti, F. Bengala, C. Berrebi, A. Besalduch, J. Biesma, D. Biron, P. Björkholm, M. Blaise, D. Blesing, N.E. Boasson, M. Bobev, D. Boccadoro, M. Bolaman, Z. Boogaerts, M.A. Bordessoule, D. Bosi, A. Aida, B.S. Bourhis, J.H. Bourikas, G. Bowen, D.T. Bregni, M. Bries, G. Brinch, L. Brittain, D. Bron, D. Brune, M. Bullorsky, E.O. Bunjes, D. Burdach, S. Burnett, A.K. Buzyn, A. Caballero, D. Cagirgan, S. Cahn, J.-Y. Canepa, C.O. Cao, A. Carella, A.M. Carrera, F.D. Carret, A.-S. Cascinu, S. Castel, V. Caswell, M. Cavanna, L. Cetto, G.L. Chapuis, B. Chasty, R. Chen, Y.-C. Chisesi, T. Chopra, R. Chybicka, A. Clark, R.E. Colombat, P. Colovic, M.D. Constenla-Figueiras, M. Contreras, M. Contu, L. Cordonnier, C. Cornelissen, J.J. Cornish, J. Coser, P. Costa, N. Coze, C. Craddock, C. Crown, J. Culligan, D.J. Danova, M. Darbyshire, P.J. Davies, J.M. de Bock, R. de Pablos Gallego, J.M. De Prijck, B. de Revel, T. De Rossi, G. De Souza, C.A. Deb, G. Degos, L. Demuynck, H. Dervenoulas, I. Di Bartolomeo, P. Di Renzo, N. Diaz, M.A. Diehl, V. Diez-Martin, J.L. Dincer, S. Giorgio, D. Dmoszynska, A. Doelken, G. Peter, P.D. Dulley, F. Easow, J. Ebell, W. Efremidis, A. Ehninger, G. Eichler, H. Eimermacher, H. Enno, A. Errazquin, L. Aguado, J.E. Everaus, H. Fagioli, F. Fanin, R. Fassas, A. Fasth, A. Faulkner, L.B. Fauser, A.A. Feldman, L. Feremans, W. Ferhanoglu, B. Fernández, M.N. Fernández-Ranada, J.M. Ferrant, A. Ferrara, F. Finke, J. Fischer, A. Fischer, J. Fitzsimons, T. Floristan, F. Forjaz de Lacerda, J.M.F. Fossati-Bellani, F. Fosser, V. Franklin, I. Freund, M. Frickhofen, N. Gabbas, A. Gadner, H. Gallamini, A. Galvin, M.C. López, J.G. García-Conde, J. Gaska, T. Gastl, G. Gedikoglu, G. Ghavamzadeh, A. Gianni, A. Gibson, B.E. Gil, J.L. Gilleece, M.H. Gisselbrecht, C. Glass, B. Gmür, J. Göbel, U. Goldman, J.M. Goldstone, A.H. San Miguel, J.D.G. González-López, M.-A. Grafakos, S. Gramatzki, M. Grañena, A. Gratecos, N. Gratwohl, A. Greinix, H.T. Gugliotta, L. Guilhot, F. Guimaraes, J.E. Gülbas, Z. Gulyuz, O. Gurman, G. Gutierrez, M.M. Haas, R. Hamladji, R.-M. Hamon, M.D. Hansen, N.E. Harhalakis, N. Harousseau, J.L. Hartenstein, R. Hartmann, C.O. Hausmaninger, H. Haznedar, R. Heit, W. Hellmann, A. Herrmann, R.P. Hertenstein, B. Hess, U. Hinterberger, W. Ho, A.D. Hoelzer, D. Holowiecki, J. Horst, H.-A. Hossfeld, D.K. Huebsch, L. Hunter, A.E. Iacopino, P. Iannitto, E. Indrák, K. Iriondo, A. Izzi, T. Jackson, G.L. Jacobs, P. Jacobsen, N. Janvier, M. Jebavy, L. Joensuu, H. Joerg, S. Jones, F.G.C. Jouet, J.P. Joyner, M.V. Juliusson, G. Jürgens, H. Kalayoglu-Besisik, S. Kalman, N. Kalmanti, M. Kansoy, S. Kansu, E. Kanz, L. Karianakis, G. Kernéis, Y. Khalifeh, O. Khomenko, V. Kienast, J. Killick, S. Kirchner, H.H. Klingebiel, T. Knauf, W. Koenigsmann, M. Koistinen, P. Koivunen, E. Kolb, H.-J. Kolbe, K. Koller, E. Komarnicki, M. Koscielniak, E. Kovacsovics, T. Kowalczyk, J.R. Koza, V. Kozak, T. Kugler, J. Kuliczkowski, K. Kvaloy, S. Labar, B. Laciura, P. Palacios, J.J.L. Lakota, J. Lambertenghi, D.G. Lange, A. Lanza, F. Isasti, R.L. Lauria, F. Le Moine, F. Leblond, V. Lelli, G. Lenhoff, S. Leon, L.A. Leoncini-Franscini, L. Leone, G. Leoni, P. Levis, A. Leyvraz, S. Liberati, M. Link, H. Linkesch, W. Liso, V. Lisukov, I.A. Littlewood, T. Ljungman, P. Locatelli, F. Losonczy, H. Lotz, J.-P. Ludwig, H. Lukac, J. Lutz, D. Macchia, P. Madrigal, A. Maiolino, A. Majolino, I. Eloy-García, J.M. Malesevic, M. Mandelli, F. Marc, A. Marcus, R. Marianska, B. Markuljak, I. Marsh, J.C.W. Martelli, M.F. Marti Tutusaus, J.M. Martin, S. Martin, M. Martinelli, G. Martínez-Rubio, A.M. Martoni, A. Maschan, A. Maschmeyer, G. Masszi, T. Mazza, P. McCann, S. Meier, C.R. Messina, C. Mettivier, V. Metzner, B. Michallet, M. Michieli, M. Michon, J. Milligan, D.W. Milone, J.H. Giuseppe, G.M. Minigo, H. Mistrik, M. Moicean, A.D. Monfardini, S. Montserrat, E. Moraleda Jimenez, J.M. Morales-Lazaro, A. Morandi, S. Morra, E. Mufti, G.J. Musso, M. Nagler, A. Nalli, G. Naparstek, E. Narni, F. Nenadov-Beck, M. Neubauer, A. Newland, A.C. Niederwieser, D. Niethammer, D. Noens, L.A. Nousiainen, T. Novik, A. Novitzky, N. Occhini, D. Odriozolas, J. Ojanguren, J.M. O’meara, A. Onat, H. Orchard, K. Ortega, J.J. Osieka, R. Ossenkoppele, G.J. Othman, B. Ovali, E. Ozcebe, O.I. Ozerkan, K. Ozturk, A. Papatryfonos, A. Parker, J.E. Pastore, M. Patrone, F. Patton, N. Pejin, D. Peñarrubia, M.J. Equiza, E.P. Peschel, C. Pession, A. Pigaditou, A. Pignon, B. Pihkala, U. Pimentel, P. Pitini, V. Podoltseva, E. Pogliani, E.M. Anna, A.P. Porta, F. Potter, M. Powles, R. Prentice, G.H. Pretnar, J. Ptushkin, V. Quarta, G. Reiter, A. Remes, K. Reykdal, S. Santasusana, J.M.R. Rifón, J. Rio, B. Rizzoli, V. Robak, T. Robinson, A.J. Rodeghiero, F. Rodríguez Fernández, J.M. Rombos, Y. Romeril, K.R. Rosenmayr, A. Rossi, J.F. Rosti, G. Rotoli, B. Rowe, J.M. Russell, N.H. Ryzhak, O. Rzepecki, P. Saglio, G. Salwender, H. Samonigg, H. Santoro, A. Sanz, M.A. Sayer, H.G. Scanni, A. Schaafsma, M.R. Schaefer, U.W. Schanz, U. Schattenberg, A. Schey, S.A.M. Schlimok, G. Schmoll, H.-J. Schots, R. Schouten, H. Schwarer, A.P. Schwerdtfeger, R. Scimè, R. Segel, E. Seger, R. Selleslag, D. Serban, M. Shamaa, S. Shaw, P.J. Siegert, W. Siena, S. Sierra, J. Simonsson, B. Singer, C.R.J. Sirchia, G. Skotnicki, A.B. Slavin, S. Snowden, J. Sotto, J.J. Tanyeli, A. Tedeschi, L. Tidefelt, U. Tissot, J.-D. Tobler, A. Tomas, J.F. Torres, J.P. Torres, G.A. Touraine, J.-L. Trneny, M. Uderzo, C. Unal, E. Unal, A. Undar, L. Urban, C. Van den Berg, H. van Marwijk, K.M. Vellenga, E. Venturini, M. Verdonck, L.F. Veys, P. Vilardell, J. Vinante, O. Visani, G. Vitek, A. Vivancos, P. Volpe, E. Vora, A. Vorlicek, J. Vowels, M. Vujic, D. Wachowiak, J. Wagner, T. Wahlin, A. Walewski, J. Wandt, H. Weissinger, F. Wijermans, P.W. Wiktor-Jedrzejczak, W. Will, A.M. Woell, E. Wörmann, B. Yaniv, I. Yesilipek, M.A. Yilmaz, U. Yong, A. Zachée, P. Zambelli, A. Zander, A.R. Zintl, F. Zoumbos, N.C. The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood Marrow Transplantation (EBMT)

Abstract

Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

148. Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment

Author

Thiel, U, Koscielniak, E, Blaeschke, F, Grunewald, T G P., Badoglio, M, Diaz, M A., Paillard, C, Prete, A, Ussowicz, M, Lang, P, Fagioli, F, Lutz, P, Ehninger, G, Schneider, P, Santucci, A, Bader, P, Gruhn, B, Faraci, M, Antunovic, Petar, Styczynski, J, Krueger, W H., Castagna, L, Rohrlich, P, Ouachee-Chardin, M, Salmon, A, Peters, C, Bregni, M, Burdach, S, Thiel, U, Koscielniak, E, Blaeschke, F, Grunewald, T G P., Badoglio, M, Diaz, M A., Paillard, C, Prete, A, Ussowicz, M, Lang, P, Fagioli, F, Lutz, P, Ehninger, G, Schneider, P, Santucci, A, Bader, P, Gruhn, B, Faraci, M, Antunovic, Petar, Styczynski, J, Krueger, W H., Castagna, L, Rohrlich, P, Ouachee-Chardin, M, Salmon, A, Peters, C, Bregni, M, and Burdach, S

Abstract

Background: Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported. less thanbrgreater than less thanbrgreater thanMethods: We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months. less thanbrgreater than less thanbrgreater thanResults: Three-year OS was 20% (s. e.+/- 8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s. e.+/- 10%) and 11% (s. e.+/- 6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR. less thanbrgreater than less thanbrgreater thanConclusion: The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials., Funding Agencies|Wilhelm Sander-Stiftung|2006.109.1|Else Kroner-Fresenius-Stiftung|P31/08//A123/07|BMBF (TranSarNet FK)|01GM087001GM1104B|Deutsche Forschungsgemeinschaft (DFG)|GR3728/2-1|AmGen and Chugai and the Deutsche Kinderkrebsstiftung|DKS 2010.07

Published
2013
Full Text
View/download PDF

149. The EBMT activity survey: 1990-2010.

Author

Passweg, J.R., Baldomero, H., Gratwohl, A., Bregni, M., Cesaro, S., Dreger, P., Witte, T.J. de, Farge-Bancel, D., Gaspar, B., Marsh, J., Mohty, M., Peters, C., Tichelli, A., Velardi, A., Elvira, C.R. de, Falkenburg, F., Sureda, A., Madrigal, A., Passweg, J.R., Baldomero, H., Gratwohl, A., Bregni, M., Cesaro, S., Dreger, P., Witte, T.J. de, Farge-Bancel, D., Gaspar, B., Marsh, J., Mohty, M., Peters, C., Tichelli, A., Velardi, A., Elvira, C.R. de, Falkenburg, F., Sureda, A., and Madrigal, A.

Abstract

1 juli 2012, Item does not contain fulltext, A total of 654 centers from 48 countries were contacted for the 2010 survey. In all, 634 centers reported a total of 33 362 hematopoietic SCT (HSCT) with 30 012 patients receiving their first transplant (12 276 allogeneic (41%) and 17 736 autologous (59%)). Main indications were leukemias: 9355 (31%; 93% allogeneic), lymphoid neoplasias specifically Non Hodgkin's lymphoma, Hodgkin's lymphoma and plasma cell disorders: 17 362 (58%; 12% allogeneic), solid tumors: 1585 (5%; 6% allogeneic) and non-malignant disorders: 1609 (6%; 88% allogeneic). There were more unrelated donors than HLA-identical sibling donors (53% versus 41%); the proportion of peripheral blood as stem cell source was 99% for autologous and 71% for allogeneic HSCT. Cord blood was primarily used in allogeneic transplants (6% of total) with three autologous cord blood HSCT being reported. The number of transplants has increased by 19% since 2005 (allogeneic 37% and autologous 9%) and continued to increase by about 1100 HSCT per year since 2000. Patterns of increase were distinct and different. The data show the development of transplantation in Europe since 1990, with the number of patients receiving a HSCT increasing from 4200 to over 30 000 annually. The most impressive trend seen is the steady increase of unrelated donor transplantation, in parallel to the availability of unrelated donors through donor registries.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results